NVIDIA AI Podcast Recursion CEO Chris Gibson on Accelerating the Biopharmaceutical Industry With AI - Ep. 230
31 snips
Aug 7, 2024 Chris Gibson, cofounder and CEO of Recursion, is transforming drug discovery using AI in the biopharmaceutical field. He discusses innovative strategies that integrate advanced data mapping and machine learning to enhance research efficiency and reduce costs. Gibson highlights the development of BioHive 2, a breakthrough computational platform, and the accessible software tool Low, which democratizes scientific workflows. He emphasizes the vital shift toward domain expertise in AI applications and culture of collaboration necessary for revolutionary drug development.
AI Snips
Chapters
Transcript
Episode notes
Decoding Biology with AI
- Recursion aims to decode biology to improve lives by using AI-driven drug discovery.
- They build maps of biological processes to guide drug development, addressing the high failure rate of clinical trials.
Recursion's Origin Story
- Chris Gibson's graduate work on cerebral cavernous malformation led to Recursion's founding.
- Traditional methods failed, but using AI on cell images identified a potential drug, now in clinical trials.
Industrializing Biological Research
- Recursion industrializes an approach of combining empirical data generation with AI analysis.
- Their robotic lab now conducts the equivalent of Gibson's five-year PhD work every 15 minutes.